IPSEN (OTCMKTS:IPSEY) Sets New 52-Week High – Here’s What Happened
by Sarita Garza · The Markets DailyIPSEN (OTCMKTS:IPSEY – Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $48.00 and last traded at $48.00, with a volume of 300 shares. The stock had previously closed at $46.30.
Analyst Ratings Changes
A number of research analysts have weighed in on IPSEY shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, February 17th. UBS Group lowered shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, IPSEN currently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on IPSEY
IPSEN Trading Up 0.7%
The firm has a fifty day moving average of $44.10 and a 200 day moving average of $38.46.
About IPSEN
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).